Stocks · News reference
Filed: 2026-08-10 AccNo: 0001437749-26-026790 Size: 490 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
Read original at benzingaDiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share
Read original at benzingaUS stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
Read original at benzinga